Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: A rare case report

Erdur F. M., Soyoral Y. U., Emre H., Begenik H., Canbaz E. T., Erkoc R.

CLINICAL BIOCHEMISTRY, vol.45, pp.162-164, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 45
  • Publication Date: 2012
  • Doi Number: 10.1016/j.clinbiochem.2011.09.025
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.162-164
  • Van Yüzüncü Yıl University Affiliated: Yes


Objectives: Fenofibrate is a fibric acid derivative that is used alone or combination with statins in the treatment of hyperlipidemia. These drugs have potential risks, including rhabdomyolysis and acute renal failure. Despite reports of rhabdomyolysis with the use of fenofibrate alone or with statin-fibrate combinations, there have been no cases of rhabdomyolysis described when fenofibrate was used alone to treat patients with chronic renal failure owing to nephrotic syndrome.